Research programme: cancer therapeutics - Cloud Pharmaceuticals/University of Florida College of Medicine

Drug Profile

Research programme: cancer therapeutics - Cloud Pharmaceuticals/University of Florida College of Medicine

Alternative Names: 8-oxodGTPase inhibitors - Cloud Pharmaceuticals/University of Florida College of Medicine; MTH1 protein inhibitors - Cloud Pharmaceuticals/University of Florida College of Medicine; MutT homolog 1 protein inhibitors - Cloud Pharmaceuticals/University of Florida College of Medicine

Latest Information Update: 30 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cloud Pharmaceuticals; University of Florida College of Medicine
  • Class Small molecules
  • Mechanism of Action 8-oxodGTPase inhibitors; Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Mar 2015 Cloud Pharmaceuticals and University of Florida College of Medicine enter into a collaboration for cancer therapeutics
  • 17 Mar 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top